Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy

Lindsay Prior, Noemi Lois*, on behalf of the EMERALD Study Group

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Downloads (Pure)

Abstract

Background/Objective
To explore acceptability by patients and health care professionals of a new surveillance pathway for people with previously treated and stable diabetic macular oedema (DMO) and/or proliferative diabetic retinopathy (PDR).

Subject/Methods
Structured discussions in 10 focus groups with patients; two with ophthalmic photographers/graders, and one with ophthalmologists, held across the UK as part of a large diagnostic accuracy study (EMERALD).

Results
The most prominent issues raised by patients concerned (i) expertise of the various professionals within clinic, (ii) quality of interactions with clinic professionals, especially the flow of information from professionals to patients, and (iii) wish to be treated holistically. Ophthalmologists suggested such issues could be best dealt with via a programme of patient education and tended to overlook deeper implications of patient concerns for the organisation of services.

Conclusion
For patients, the clinical service should not only include the identification and treatment of disease but also exchange of information, reassurance, and mitigation of anxiety. Alterations in the standard care pathway need to take account of such concerns and their implications, in addition to any assessments of ‘efficiency’ that may flow from changes in diagnostic technology, or the division of professional labour.

Original languageEnglish
Pages (from-to)1155-1159
Number of pages5
JournalEye
Volume37
Issue number6
Early online date06 May 2022
DOIs
Publication statusPublished - Apr 2023

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Fingerprint

Dive into the research topics of 'Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy'. Together they form a unique fingerprint.

Cite this